Special Issue

Diagnosis, Treatment, and Survivorship of Lymphoma in the Era of Personalized Medicine

Message from the Guest Editor

Personalized medicine offers the possibility of identifying HL patients that can be cured with less toxic regimens in an effort to minimize adverse effects and improve patient quality of life. With recent advances such as next-generation sequencing (NGS), personalized medicine offers opportunities to diagnose NHL patients earlier, tailor treatment based on genomic or molecular alterations, minimize adverse effects, and detect relapsed disease sooner.   This Special Issue of the Journal of Personalized Medicine aims to highlight the recent developments in personalized approaches to the diagnosis, treatment, and survivorship of lymphoma patients. Articles or comprehensive reviews on the identification and characterization of novel biomarkers for disease diagnosis, therapy selection, and monitoring, as well as those that describe new methods and approaches used for these purposes, are welcome.

Guest Editor

Dr. Andrew Ip

Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA

Deadline for manuscript submissions

20 January 2026

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).